Who are Trileptal®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xylocaine with Epinephrine, Tegretol®, Xylocaine and Dexamethasone, Plain bupivacaine, Lidocaine 1%/Epi 1:200000, Proparacaine Ophthalmic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trileptal.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Trileptal® — Competitive Intelligence Brief

Trileptal® (Trileptal®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant; sodium channel blocker. Area: Neurology.

marketed Anticonvulsant; sodium channel blocker Voltage-gated sodium channels Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Trileptal® (Trileptal®) — Teva Pharmaceuticals USA. Oxcarbazepine blocks voltage-gated sodium channels in neuronal membranes, reducing repetitive neuronal firing and stabilizing hyperexcited neural tissue.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Trileptal® TARGET	Trileptal®	Teva Pharmaceuticals USA	marketed	Anticonvulsant; sodium channel blocker	Voltage-gated sodium channels
Xylocaine with Epinephrine	Xylocaine with Epinephrine	Vrije Universiteit Brussel	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors
Tegretol®	Tegretol®	University of Malaya	marketed	Anticonvulsant; mood stabilizer	Voltage-gated sodium channels
Xylocaine and Dexamethasone	Xylocaine and Dexamethasone	University of Jordan	marketed	Local anesthetic + corticosteroid combination	Voltage-gated sodium channels (lidocaine); glucocorticoid receptor (dexamethasone)
Plain bupivacaine	Plain bupivacaine	Fayoum University Hospital	marketed	Local anesthetic	Voltage-gated sodium channels
Lidocaine 1%/Epi 1:200000	Lidocaine 1%/Epi 1:200000	Wahba bakhet	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels
Proparacaine Ophthalmic	Proparacaine Ophthalmic	American Genomics, LLC	marketed	Local anesthetic (ester)	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant; sodium channel blocker class)

Korean Epilepsy Society · 1 drug in this class
Mario Negri Institute for Pharmacological Research · 1 drug in this class
Teva Pharmaceuticals USA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trileptal® — Competitive Intelligence Brief. https://druglandscape.com/ci/trileptal. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab